PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Article content A Potentially Expedited Path Toward FDA Approval PharmaTher and Dr. Cassidy plan to work with the FDA to find an efficient path to approval for KetaMist. Leveraging PharmaTher’s FDA-Approved Ketamine Foundation PharmaTher previously obtained FDA approval for Ketamine Hydrochloride Injection USP under ANDA #217858, demonstrating the Company’s ability to complete the regulatory, manufacturing, analytical and quality requirements necessary to secure an FDA ketamine approval. “KetaMist fits our strategy perfectly-a doctor-developed ketamine treatment with over 9,000 patient uses and a path to FDA approval. Near-Term Development Priorities The collaboration activities will include preparing an FDA meeting package to obtain guidance for a potentially accelerated path toward FDA approval. About PharmaTher PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty pharmaceutical company focused on developing, acquiring and commercializing personalized medicines and enabling technologies, with an emphasis on peptides and psychedelics.